These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
716 related articles for article (PubMed ID: 18434717)
21. Hyponatremia in neurologic patients: consequences and approaches to treatment. Diringer MN; Zazulia AR Neurologist; 2006 May; 12(3):117-26. PubMed ID: 16688013 [TBL] [Abstract][Full Text] [Related]
22. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Aronson D; Verbalis JG; Mueller M; Krum H; Eur J Heart Fail; 2011 Mar; 13(3):327-36. PubMed ID: 21199833 [TBL] [Abstract][Full Text] [Related]
23. Neurological impact of vasopressin dysregulation and hyponatremia. Bhardwaj A Ann Neurol; 2006 Feb; 59(2):229-36. PubMed ID: 16437573 [TBL] [Abstract][Full Text] [Related]
24. Vasopressin antagonists: role in the management of hyponatremia. Yeates KE; Morton AR Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788 [TBL] [Abstract][Full Text] [Related]
25. [Vasopressin antagonists in treatment of hyponatremia]. Olszewski W; Głuszek J Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383 [TBL] [Abstract][Full Text] [Related]
26. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of vasopressin receptor antagonists. Ali F; Guglin M; Vaitkevicius P; Ghali JK Drugs; 2007; 67(6):847-58. PubMed ID: 17428103 [TBL] [Abstract][Full Text] [Related]
28. Hyponatremia: a problem-solving approach to clinical cases. Assadi F J Nephrol; 2012; 25(4):473-80. PubMed ID: 22307436 [TBL] [Abstract][Full Text] [Related]
30. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism. Rosner MH; Ronco C Congest Heart Fail; 2010 Jul; 16 Suppl 1():S7-14. PubMed ID: 20653716 [TBL] [Abstract][Full Text] [Related]
31. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Verbalis JG Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Mao ZL; Stalker D; Keirns J Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403 [TBL] [Abstract][Full Text] [Related]
33. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. Ghali JK; Zmily HD; Farah JO; Daifallah S IDrugs; 2010 Nov; 13(11):782-92. PubMed ID: 21046526 [TBL] [Abstract][Full Text] [Related]
35. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan. Ferguson-Myrthil N Cardiol Rev; 2010; 18(6):313-21. PubMed ID: 20926941 [TBL] [Abstract][Full Text] [Related]
36. Management of hyponatremia in heart failure: role of tolvaptan. Albert NM; Chase S J Cardiovasc Nurs; 2013; 28(2):176-86. PubMed ID: 22635058 [TBL] [Abstract][Full Text] [Related]